In the first half of 2026, Replex AD Skopje reported robust performance across its pharmaceutical segment, recording combined revenues totaling 13.9 million euros. The company’s financial results indicate significant strength within the domestic market, which served as the primary driver of revenue growth during the period. Specific figures show that sales within the domestic market generated 4.8 million euros.
This represents a substantial year-over-year increase of 24%, solidifying the company’s standing within the local pharmaceutical sector. While export markets contributed 9.1 million euros to the overall revenue, the increased contribution from local sales was notable. This growth has successfully elevated the domestic market’s share to 35% of the total revenue recorded in the first six months of the year.
The financial data confirms a positive structural shift in the company’s revenue composition, pointing to strengthening demand and market penetration within its home country. These results underscore the stability and expanding importance of the local market to Replex AD Skopje’s overall financial structure heading into the remainder of 2026.
Topics: #domestic #market #first
